Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX plus Atezolizumab and Bevacizumab in Advanced HCC
NCT07192185Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, folinic acid, atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Sep 2025; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07192185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192185.